Mercer Global Advisors
LYEL icon

Mercer Global Advisors’s Lyell Immunopharma LYEL Stock Holding History

Mercer Global Advisors’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,020
Closed -$58.6K – 2013
2024
Q2 		$58.6K Sell
2,020
-120
-6% -$5.71K ﹤0.01% 1901
2024
Q1 		$95K Buy
+2,140
New +$91.6K ﹤0.01% 1857

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
WA
WuXi AppTec Shanghai, China $19M AUM 20.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mercer Global Advisors's LYEL Position: Q3 2024 in Review

Mercer Global Advisors sold out of Lyell Immunopharma (LYEL) in Q3 2024, closing a stake of 2,020 shares — an estimated $58.6K sold.

Mercer Global Advisors first reported a position in LYEL in Q1 2024 and held it in 2 quarters. The position peaked at $95K in Q1 2024. 117 funds tracked by Wall St. Rank hold LYEL as of Q3 2024.

  • Mercer Global Advisors reported no remaining Lyell Immunopharma position as of Q3 2024 after selling out during the quarter.
  • Mercer Global Advisors sold 2,020 Lyell Immunopharma shares in Q3 2024, an estimated $58.6K.
  • Mercer Global Advisors first reported a position in Lyell Immunopharma in Q1 2024 and held it in 2 quarters.
  • Mercer Global Advisors's Lyell Immunopharma position peaked at $95K in Q1 2024.
  • 117 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q3 2024.

Based on Mercer Global Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.